PD-L1 IHC — Clono Ventana SP142
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BIO-PDL1-SP142-CLONE |
|---|---|
| Tipo | Biomarcador |
| Aliaces | PD-L1 SP142 (Ventana)PD-L1 ІГХ — клон Ventana SP142SP142VENTANA PD-L1 (SP142)Ventana SP142 |
| Situación | reviewed 2026-04-29 | pending_clinical_signoff |
| Enfermedades | DIS-NSCLC |
| Fuentes | SRC-NCCN-BLADDER-2025 SRC-NCCN-BREAST-2025 SRC-NCCN-NSCLC-2025 |
Datos sobre biomarcadores
| Tipo de biomarcador | protein_expression_ihc |
|---|---|
| Medición | MétodoIHC with VENTANA PD-L1 (SP142) Assay on BenchMark ULTRA / XT. Scoring is IMMUNE-CELL-WEIGHTED (distinct from 22C3 / SP263): - TNBC: IC score = % tumor area occupied by PD-L1+ immune cells of any intensity; positive cut-off IC ≥1%. - Urothelial (historical): IC ≥5%. - NSCLC (atezolizumab IMpower150 era): TC ≥50% OR IC ≥10% ("TC3 or IC3"). UnidadesIC% (área de células inmunes) y/o TC% (tumor-células %), específico del ensayo Alcance típico
|
| Productos químicos y químicos | BIO-PDL1-EXPRESSION BIO-PDL1-TPS |
Notas
Companion-diagnostic clone-specific entity for atezolizumab. Important for engine: a TNBC patient with a 22C3 CPS result CANNOT be routed through an SP142-IC-based atezo regimen and vice versa — clones are not interchangeable. Render layer should surface assay-mismatch warnings. TRIAL ANCHOR: IMpassion130 (Schmid et al, NEJM 2018) — primary validating trial; full Source stub TBD (flag for source-ingest follow-up). Currently citing NCCN guidelines that summarize the evidence and SP142-specific cut-points.
Utilizado por
Indicación
IND-NSCLC-ADJUVANT-ATEZO-PDL1POS- IND-NSCLC-ADJUVANT-ATEZO-PDL1POS